United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i), tamsulosin hydrochloride (unii: 11sv1951mr) (tamsulosin - unii:g3p28oml5i) - dutasteride 0.5 mg - jalyn (dutasteride and tamsulosin hydrochloride) capsules are indicated for the treatment of symptomatic bph in men with an enlarged prostate. dutasteride-containing products, including jalyn, are not approved for the prevention of prostate cancer. jalyn is contraindicated for use in: •   pregnancy. dutasteride use is contraindicated in females who are pregnant. in animal reproduction and developmental toxicity studies, dutasteride inhibited development of male fetus external genitalia. therefore, jalyn may cause fetal harm when administered to a pregnant female [see warnings and precautions ( 5.6), use in specific populations ( 8.1)] . •   patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema, urticaria, pruritus, respiratory symptoms) to dutasteride, other 5-alpha-reductase inhibitors, tamsulosin, or any other component of jalyn [see adverse reactions (6.2) ] . risk summary jalyn is contraindicated for use in pregnancy because it may cause

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - dutasteride 0.5 mg - avodart (dutasteride) soft gelatin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: avodart in combination with the alpha-adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic bph in men with an enlarged prostate. avodart is not approved for the prevention of prostate cancer. avodart is contraindicated for use in: risk summary avodart is contraindicated for use in pregnancy because it may cause harm to the male fetus [see contraindications (4)] . avodart is not indicated for use in women. avodart is a 5 alpha‑reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (dht), a hormone necessary for normal development of male genitalia. abnormalities in the genitalia of male fetuses is an expected physiological consequence of inhibition of this conversion. these results are similar to observations in male infants with genetic 5 alpha‑reductase deficiency. in the u.s. general populat

United States - English - NLM (National Library of Medicine)

a-s medication solutions - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - dutasteride capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: - improve symptoms, - reduce the risk of acute urinary retention (aur), and - reduce the risk of the need for bph-related surgery. dutasteride capsules in combination with the alpha adrenergic antagonist, tamsulosin, are indicated for the treatment of symptomatic bph in men with an enlarged prostate. dutasteride capsules are not approved for the prevention of prostate cancer. dutasteride, usp is contraindicated for use in: - pregnancy. in animal reproduction and developmental toxicity studies, dutasteride, usp inhibited development of male fetus external genitalia. therefore, dutasteride, usp may cause fetal harm when administered to a pregnant woman. if dutasteride, usp is used during pregnancy or if the patient becomes pregnant while taking dutasteride, usp, the patient should be apprised of the potential hazard to the fetus [see warnings and precautions (5.4), use in s

United States - English - NLM (National Library of Medicine)

lake erie medical & surgcial supply dba quality care products llc - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - dutasteride 0.5 mg

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - dutasteride 0.5 mg

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) -

United States - English - NLM (National Library of Medicine)

woodward pharma services llc - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - avodart (dutasteride) soft gelatin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: avodart in combination with the alpha-adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic bph in men with an enlarged prostate. avodart is not approved for the prevention of prostate cancer. avodart is contraindicated for use in: risk summary avodart is contraindicated for use in pregnancy because it may cause harm to the male fetus [see contraindications (4)] . avodart is not indicated for use in women. avodart is a 5 alpha‑reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (dht), a hormone necessary for normal development of male genitalia. abnormalities in the genitalia of male fetuses is an expected physiological consequence of inhibition of this conversion. these results are similar to observations in male infants with genetic 5 alpha‑reductase deficiency. in the u.s. general populat

United States - English - NLM (National Library of Medicine)

waylis therapeutics llc - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - avodart (dutasteride) soft gelatin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: avodart in combination with the alpha-adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic bph in men with an enlarged prostate. avodart is not approved for the prevention of prostate cancer. avodart is contraindicated for use in: risk summary avodart is contraindicated for use in pregnancy because it may cause harm to the male fetus [see contraindications (4)] . avodart is not indicated for use in women. avodart is a 5 alpha‑reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (dht), a hormone necessary for normal development of male genitalia. abnormalities in the genitalia of male fetuses is an expected physiological consequence of inhibition of this conversion. these results are similar to observations in male infants with genetic 5 alpha‑reductase deficiency. in the u.s. general populat

Malta - English - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - dutasteride - soft capsule - dutasteride 0.5 mg - urologicals

Malta - English - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - dutasteride, tamsulosin hydrochloride - hard capsule - dutasteride 0.5 mg tamsulosin hydrochloride 0.4 mg - urologicals